Related Experiment Video
Updated: Jun 23, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Novel therapeutic agents for osteosarcoma
Kathleen O'Day1, Richard Gorlick
1Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal 3rd floor, Bronx, NY 10467, USA. koday@montefiore.org
Abstract:
Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of patients with metastatic disease at diagnosis will relapse. Survival for these patients has remained unchanged over the past 20 years. A number of novel agents in various stages of development hold promise for improving therapy for patients with osteosarcoma. This article will focus on novel therapeutic approaches, including agents targeting signal-transduction pathways, inhibitors of the tumor microenvironment and immunomodulatory agents, as well as overcoming resistance mechanisms and the use of novel delivery mechanisms.
Insights
New treatments are being developed for osteosarcoma, a common childhood bone cancer. These novel therapies aim to improve outcomes for patients who relapse after standard chemotherapy and surgery.
Area of Science:
- Pediatric Oncology
- Skeletal Oncology
- Cancer Therapeutics
Background:
- Osteosarcoma is the most frequent primary malignant bone tumor in children.
- Current treatments including chemotherapy and surgery have limited efficacy, with high relapse rates (30% localized, 80% metastatic).
- Patient survival has not improved in two decades, highlighting an urgent need for new therapeutic strategies.
Purpose of the Study:
- To review novel therapeutic approaches for osteosarcoma.
- To discuss emerging agents targeting signal-transduction pathways, tumor microenvironment, and immunomodulation.
- To explore strategies for overcoming treatment resistance and novel drug delivery mechanisms.
Main Methods:
- Review of current literature on novel osteosarcoma therapeutics.
- Focus on agents in various stages of clinical development.
- Discussion of preclinical and clinical findings related to new treatment modalities.
Main Results:
- Several novel agents show promise in preclinical and early clinical studies.
- Targeting specific signal-transduction pathways offers a new avenue for treatment.
- Inhibitors of the tumor microenvironment and immunomodulatory agents are emerging as potential therapies.
- Strategies to overcome drug resistance and novel delivery systems are under investigation.
Conclusions:
- Novel therapeutic agents targeting signal-transduction pathways, the tumor microenvironment, and immune responses hold significant promise for improving osteosarcoma treatment.
- Addressing treatment resistance and employing innovative drug delivery methods are crucial for enhancing therapeutic efficacy.
- Further research and clinical trials are essential to translate these promising approaches into improved patient survival for osteosarcoma.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
01:27Tumor Immunotherapy